Cargando…
A 4-Week, Two-Center, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of EOPatch in Well-Controlled Type 1 Diabetes Mellitus
This study evaluated the safety and efficacy of tubeless patch pump called EOPatch in patients with well-controlled type 1 diabetes mellitus (T1DM). This 4-week, two-center, open-label, single-arm study enrolled 10 adult patients diagnosed with T1DM with glycosylated hemoglobin less than 7.5%. The c...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Diabetes Association
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9723198/ https://www.ncbi.nlm.nih.gov/pubmed/35255546 http://dx.doi.org/10.4093/dmj.2021.0299 |
_version_ | 1784844113996152832 |
---|---|
author | Park, Jiyun Park, Nammi Han, Sangjin Lee, You-Bin Kim, Gyuri Jin, Sang-Man Lee, Woo Je Kim, Jae Hyeon |
author_facet | Park, Jiyun Park, Nammi Han, Sangjin Lee, You-Bin Kim, Gyuri Jin, Sang-Man Lee, Woo Je Kim, Jae Hyeon |
author_sort | Park, Jiyun |
collection | PubMed |
description | This study evaluated the safety and efficacy of tubeless patch pump called EOPatch in patients with well-controlled type 1 diabetes mellitus (T1DM). This 4-week, two-center, open-label, single-arm study enrolled 10 adult patients diagnosed with T1DM with glycosylated hemoglobin less than 7.5%. The co-primary end points were patch pump usage time for one attachment and number of serious adverse events related to the patch pump. The secondary end points were total amount of insulin injected per patch and changes in glycemic parameters including continuous glucose monitoring data compared to those at study entry. The median usage time per patch was 84.00 hours (interquartile range, 64.50 to 92.50). Serious adverse events did not occur during the trial. Four weeks later, time in range 70 to 180 mg/dL was significantly improved (70.71%±17.14 % vs. 82.96%±9.14%, P=0.01). The times spent below range (<54 mg/dL) and above range (>180 mg/dL) also improved (All P<0.05). Four-week treatment with a tubeless patch pump was safe and led to clinical improvement in glycemic control. |
format | Online Article Text |
id | pubmed-9723198 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Korean Diabetes Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-97231982022-12-14 A 4-Week, Two-Center, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of EOPatch in Well-Controlled Type 1 Diabetes Mellitus Park, Jiyun Park, Nammi Han, Sangjin Lee, You-Bin Kim, Gyuri Jin, Sang-Man Lee, Woo Je Kim, Jae Hyeon Diabetes Metab J Short Communication This study evaluated the safety and efficacy of tubeless patch pump called EOPatch in patients with well-controlled type 1 diabetes mellitus (T1DM). This 4-week, two-center, open-label, single-arm study enrolled 10 adult patients diagnosed with T1DM with glycosylated hemoglobin less than 7.5%. The co-primary end points were patch pump usage time for one attachment and number of serious adverse events related to the patch pump. The secondary end points were total amount of insulin injected per patch and changes in glycemic parameters including continuous glucose monitoring data compared to those at study entry. The median usage time per patch was 84.00 hours (interquartile range, 64.50 to 92.50). Serious adverse events did not occur during the trial. Four weeks later, time in range 70 to 180 mg/dL was significantly improved (70.71%±17.14 % vs. 82.96%±9.14%, P=0.01). The times spent below range (<54 mg/dL) and above range (>180 mg/dL) also improved (All P<0.05). Four-week treatment with a tubeless patch pump was safe and led to clinical improvement in glycemic control. Korean Diabetes Association 2022-11 2022-03-08 /pmc/articles/PMC9723198/ /pubmed/35255546 http://dx.doi.org/10.4093/dmj.2021.0299 Text en Copyright © 2022 Korean Diabetes Association https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Short Communication Park, Jiyun Park, Nammi Han, Sangjin Lee, You-Bin Kim, Gyuri Jin, Sang-Man Lee, Woo Je Kim, Jae Hyeon A 4-Week, Two-Center, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of EOPatch in Well-Controlled Type 1 Diabetes Mellitus |
title | A 4-Week, Two-Center, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of EOPatch in Well-Controlled Type 1 Diabetes Mellitus |
title_full | A 4-Week, Two-Center, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of EOPatch in Well-Controlled Type 1 Diabetes Mellitus |
title_fullStr | A 4-Week, Two-Center, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of EOPatch in Well-Controlled Type 1 Diabetes Mellitus |
title_full_unstemmed | A 4-Week, Two-Center, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of EOPatch in Well-Controlled Type 1 Diabetes Mellitus |
title_short | A 4-Week, Two-Center, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of EOPatch in Well-Controlled Type 1 Diabetes Mellitus |
title_sort | 4-week, two-center, open-label, single-arm study to evaluate the safety and efficacy of eopatch in well-controlled type 1 diabetes mellitus |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9723198/ https://www.ncbi.nlm.nih.gov/pubmed/35255546 http://dx.doi.org/10.4093/dmj.2021.0299 |
work_keys_str_mv | AT parkjiyun a4weektwocenteropenlabelsinglearmstudytoevaluatethesafetyandefficacyofeopatchinwellcontrolledtype1diabetesmellitus AT parknammi a4weektwocenteropenlabelsinglearmstudytoevaluatethesafetyandefficacyofeopatchinwellcontrolledtype1diabetesmellitus AT hansangjin a4weektwocenteropenlabelsinglearmstudytoevaluatethesafetyandefficacyofeopatchinwellcontrolledtype1diabetesmellitus AT leeyoubin a4weektwocenteropenlabelsinglearmstudytoevaluatethesafetyandefficacyofeopatchinwellcontrolledtype1diabetesmellitus AT kimgyuri a4weektwocenteropenlabelsinglearmstudytoevaluatethesafetyandefficacyofeopatchinwellcontrolledtype1diabetesmellitus AT jinsangman a4weektwocenteropenlabelsinglearmstudytoevaluatethesafetyandefficacyofeopatchinwellcontrolledtype1diabetesmellitus AT leewooje a4weektwocenteropenlabelsinglearmstudytoevaluatethesafetyandefficacyofeopatchinwellcontrolledtype1diabetesmellitus AT kimjaehyeon a4weektwocenteropenlabelsinglearmstudytoevaluatethesafetyandefficacyofeopatchinwellcontrolledtype1diabetesmellitus AT parkjiyun 4weektwocenteropenlabelsinglearmstudytoevaluatethesafetyandefficacyofeopatchinwellcontrolledtype1diabetesmellitus AT parknammi 4weektwocenteropenlabelsinglearmstudytoevaluatethesafetyandefficacyofeopatchinwellcontrolledtype1diabetesmellitus AT hansangjin 4weektwocenteropenlabelsinglearmstudytoevaluatethesafetyandefficacyofeopatchinwellcontrolledtype1diabetesmellitus AT leeyoubin 4weektwocenteropenlabelsinglearmstudytoevaluatethesafetyandefficacyofeopatchinwellcontrolledtype1diabetesmellitus AT kimgyuri 4weektwocenteropenlabelsinglearmstudytoevaluatethesafetyandefficacyofeopatchinwellcontrolledtype1diabetesmellitus AT jinsangman 4weektwocenteropenlabelsinglearmstudytoevaluatethesafetyandefficacyofeopatchinwellcontrolledtype1diabetesmellitus AT leewooje 4weektwocenteropenlabelsinglearmstudytoevaluatethesafetyandefficacyofeopatchinwellcontrolledtype1diabetesmellitus AT kimjaehyeon 4weektwocenteropenlabelsinglearmstudytoevaluatethesafetyandefficacyofeopatchinwellcontrolledtype1diabetesmellitus |